U.S. stock night trading volatility: Strong revenue expectations fail to mask profit concerns, Alnylam Pharma falls 3.15% in night trading

U.S. Stock Market After-Hours Movements Alnylam Pharma fell 3.15% in after-hours trading. Based on recent news, On January 11, Alnylam Pharma released its full-year product revenue guidance for 2026, expecting combined net product revenues from AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO to be between $4.9 billion and $5.3 billion, a 71% increase from the midpoint of 2025. Despite strong revenue expectations, the market has concerns about its future profitability, leading to a decline in stock price. On January 11, Alnylam Pharma announced preliminary global net product revenues for the fourth quarter, with AMVUTTRA and ONPATTRO at approximately $827 million and $32 million, respectively, a 151% increase from the fourth quarter of 2024. However, the market is skeptical about whether this high growth can be sustained, further exacerbating stock price volatility. On January 11, Alnylam Pharma announced that it will release its complete financial results in February 2026. Investors are taking a wait-and-see approach regarding the upcoming financial report, leading to short-term stock price fluctuations. There are concerns in the market about Alnylam Pharma's future profitability. Stocks with High Trading Volume in the Industry Recursion rose 1.93% in after-hours trading. Based on recent key news: On January 9, Blake Borgeson, a director of Recursion Pharmaceuticals, reported the sale of company common stock. This move may raise concerns in the market about insider confidence in the company, affecting stock price volatility. Source: EDGAR system disclosure. On January 10, Recursion Pharmaceuticals submitted a preliminary beneficial ownership statement, listing Chief Scientific Officer David Hallett as a beneficial owner. This information may trigger market attention to the company's governance structure, impacting stock price. Source: EDGAR system disclosure. On January 11, MarketBeat noted that Recursion Pharmaceuticals was not included in the list of five stocks recommended by top analysts. Analysts maintained a hold rating on Recursion, which may lead to a cautious attitude among investors regarding its future performance. Source: MarketBeat analysis report. The biotechnology sector has been experiencing significant volatility recently, warranting attention. Mereo Biopharma rose 16.53% in after-hours trading, with a trading volume of $1.2 million and no significant recent news. The trading is active, with clear capital flow, and considering sector and industry trends, the stock shows notable volatility, with specific reasons needing further observation. MoonLake increased by 9.14%. Based on recent key news: On January 10, several analysts raised their target price for MoonLake, driving the stock price up. Analysts are optimistic about its future performance, believing that its upcoming BLA application will have a positive impact, resulting in the stock price increase On January 9th, the meeting results between MoonLake and the FDA indicated that no additional clinical trials are needed, which boosted market confidence. The FDA's recommendations clarified the BLA application process for MoonLake, resulting in a rise in stock price. On January 9th, analysts maintained a buy rating, expecting that trial results in multiple disease areas will bring additional growth potential. Analysts believe that SLK has significant potential in various inflammatory disease areas, maintaining a buy rating, which led to an increase in stock price. The biotechnology industry has been active recently, with noticeable capital inflows